Bo R. Rueda

Oct 5, 2024 | nature.com | Bo R. Rueda |Rakesh K. Jain

AbstractOvarian cancer (OvCa) is the most lethal of the gynecologic malignancies. Immune checkpoint inhibitors, which have revolutionized the treatment of multiple malignancies, have had limited efficacy in OvCa patients. This lack of effectiveness is partly due to the abnormal ovarian tumor microenvironment (TME), displaying a desmoplastic, highly fibrotic extracellular matrix.

May 7, 2024 | nature.com | Yumin Wang |Xiaolan Zhu |Aiko Nagayama |SangHoon Lee |Siang-Boon Koh |Bo R. Rueda | +4 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-45693-2, published online 21 February 2024In the original version of the published article, the Acknowledgements section was missing a funding source number for Jian Ouyang: National Institutes of Health grant P50 CA274158 (JO). The correct Acknowledgements paragraph is:National Institutes of Health grant R01 GM118833 and CA282939 (LL). National Institutes of Health grant R01 CA181368, CA183976, and 1R21CA237964 (Xi. W).